IN SEARCH OF NEW LEAD COMPOUNDS FOR TRYPANOSOMIASIS DRUG DESIGN - A PROTEIN STRUCTURE-BASED LINKED-FRAGMENT APPROACH

被引:60
|
作者
VERLINDE, CLMJ
RUDENKO, G
HOL, WGJ
机构
[1] BIOSON Research Institute, University of Groningen, Groningen, 9747 AG
关键词
MODULAR STRUCTURE-BASED INHIBITOR DESIGN; CHEMICAL DATABASE; TRIOSEPHOSPHATE ISOMERASE;
D O I
10.1007/BF00129424
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A modular method for pursuing structure-based inhibitor design in the framework of a design cycle is presented. The approach entails four stages: (1) a design pathway is defined in the three-dimensional structure of a target protein; (2) this pathway is divided into subregions; (3) complementary building blocks, also called fragments, are designed in each subregion; complementarity is defined in terms of shape, hydrophobicity, hydrogen bond properties and electrostatics; and (4) fragments from different subregions are linked into potential lead compounds. Stages (3) and (4) are qualitatively guided by force-field calculations. In addition, the designed fragments serve as entries for retrieving existing compounds from chemical databases. This linked-fragment approach has been applied in the design of potentially selective inhibitors of triosephosphate isomerase from Trypanosoma brucei, the causative agent of sleeping sickness.
引用
收藏
页码:131 / 147
页数:17
相关论文
共 50 条
  • [41] Protein structure-based drug design: applications, limitations and future developments
    Alexander Hillisch
    Chemistry Central Journal, 2 (Suppl 1)
  • [42] Automated protein-ligand crystallography for structure-based drug design
    Mooij, Wijnand T. M.
    Hartshorn, Michael J.
    Tickle, Ian J.
    Sharff, Andrew J.
    Verdonk, Marcel L.
    Jhoti, Harren
    CHEMMEDCHEM, 2006, 1 (08) : 827 - 838
  • [43] leadXPro - Structure-Based Drug Design on Membrane Protein Targets at SwissFEL
    Cheng, Robert
    Markovic, Sandra
    Botte, Mathieu
    Hennig, Michael
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2016, 72 : S211 - S211
  • [44] Protein structure-based drug design: from docking to molecular dynamics
    Sledz, Pawel
    Caflisch, Amedeo
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2018, 48 : 93 - 102
  • [45] Beyond the Virtual Screening Paradigm: Structure-Based Searching for New Lead Compounds
    Schlosser, Jochen
    Rarey, Matthias
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2009, 49 (04) : 800 - 809
  • [46] Structure-based integrative computational and experimental approach for the optimization of drug design
    Morikis, D
    Floudas, CA
    Lambris, JD
    COMPUTATIONAL SCIENCE - ICCS 2005, PT 2, 2005, 3515 : 680 - 688
  • [47] Structure-based drug design for new therapies for Leishmaniasis and Chagas disease
    Pohl, E.
    Silber, A. M.
    Freitag-Pohl, S.
    Sowerby, K.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2024, 80
  • [48] Structure-Based Design of New AIDS Drugs: Overcoming Drug Resistance
    Das, Kalyan
    Clark, Arthur D., Jr.
    Lewi, Paul J.
    Hughes, Stephen H.
    Janssen, Paul A. J.
    Arnold, Eddy
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2005, 61 : C119 - C119
  • [49] Systems Biology Brings New Dimensions for Structure-Based Drug Design
    Pei, Jianfeng
    Yin, Ning
    Ma, Xiaomin
    Lai, Luhua
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2014, 136 (33) : 11556 - 11565
  • [50] Saccharin: A lead compound for structure-based drug design of carbonic anhydrase IX inhibitors
    Mahon, Brian P.
    Hendon, Alex M.
    Driscoll, Jenna M.
    Rankin, Gregory M.
    Poulsen, Sally-Ann
    Supuran, Claudiu T.
    McKenna, Robert
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (04) : 849 - 854